Why the study?
Over half of individuals with hypertension fail to achieve recommended treatment goals with medications and lifestyle interventions, creating a need for guidance on selecting appropriate candidates for renal denervation in resistant hypertension.
An expert consensus from India provides a practical triage tool to optimize patient selection for renal denervation in resistant hypertension.
May refine RDN candidate selection in resistant hypertension; leaves open prospective validation before practice change.
Despite the availability of medications and advocacy for lifestyle interventions, over half of individuals with hypertension do not achieve recommended treatment goals owing to limitations with medications, such as high cost, side effects, and poor adherence. Renal denervation (RDN), a minimally invasive endovascular procedure targeting sympathetic nerves near the renal arteries, is gaining recognition as a safe and effective adjunctive therapy for blood pressure control in resistant hypertension, supported by several clinical trials and meta-analyses. Recognising the clinical complexity of resistant hypertension, a group of hypertension experts from India convened to develop an "RDN triage tool" to guide clinicians in selecting appropriate candidates for RDN therapy based on demographics, blood pressure, renal function, and cardiac status. This approach is supported by clinical evidence and expert recommendations and aims to optimise patient selection for RDN therapy, aid clinical decision-making, minimise risks, and enhance patient outcomes.
No takes yet. Share an insight, caveat, or question.
Kalra et al. (2026) studied resistant hypertension. Renal denervation (RDN) triage tool was evaluated. An RDN triage tool was developed by hypertension experts from India to guide clinicians in selecting appropriate candidates for renal denervation therapy in resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: